Skip to main content
. Author manuscript; available in PMC: 2024 May 12.
Published in final edited form as: Nat Biomed Eng. 2023 Nov 27;8(4):479–494. doi: 10.1038/s41551-023-01134-x

Extended Data Fig. 4 |. Pharmacological suppression of the beating rate increase blunts the deterioration of EHT contractility.

Extended Data Fig. 4 |

a, Experimental outline: EHTs (SCVI-273) were tachypaced for 5 days with or without drug treatment. Contractility was measured before and after tachypacing. b, Effect of carvedilol (250 ng/mL) on the beating rate (unpaced or paced) and the contractile force of tachypaced EHTs. n = 4 EHTs per group. c, Effect of FK506 (5 μM) on the beating rate (unpaced or paced) and the contractile force of tachypaced EHTs. n = 8 EHTs for the beating rate measurements and n = 5 EHTs for contractile force measurements. d, Effect of ivabradine (5 μM) on the beating rate (unpaced or paced) and the contractile force of tachypaced EHTs. n = 4 untreated EHTs and n = 8 ivabradine-treated EHTs. Unpaired Student’s t-test. Data are displayed as mean ± s.e.m.